1 / 2

Low Risk GTD Phase III trial

Low Risk GTD Phase III trial. Schema. Pulse Act-D 1.25 mg/m2 every 2 weeks IV. Low Risk GTD WHO Score* 0-6 * WHO 2002 scoring. Randomize. Multiday Methotrexate Institutional preference of Either 0.4mg/kg daily x5 IV q 2weeks or CC 8 day regimen with leukovorin rescue.

whilemina-good
Download Presentation

Low Risk GTD Phase III trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Low Risk GTD Phase III trial

  2. Schema Pulse Act-D 1.25 mg/m2 every 2 weeks IV Low Risk GTD WHO Score* 0-6 * WHO 2002 scoring Randomize Multiday Methotrexate Institutional preference of Either 0.4mg/kg daily x5 IV q 2weeks or CC 8 day regimen with leukovorin rescue Statistical considerations: power to test if experimental (MTX) arm is superior based on GOG 174: based on CR .70 for control arm and .80 for experimental arm power 90%

More Related